Second Cancer Risk Awareness Crucial for Hodgkin Lymphoma Survivors

Share this content:
Second Cancer Risk Awareness Crucial for Hodgkin Lymphoma Survivors
Second Cancer Risk Awareness Crucial for Hodgkin Lymphoma Survivors

Awareness of the increased risk for developing subsequent malignancies remains of great importance for survivors of Hodgkin's lymphoma and for their physicians, according to a study published in The New England Journal of Medicine.1

Although it is known that Hodgkin's lymphoma survivors are at an increased risk for treatment-related subsequent malignant neoplasms, there is limited evidence on the effect of less toxic treatments, particularly those introduced in the late 1980s, on the long-term risk of a second malignancy. Therefore, researchers sought to compare the risk of a second cancer among these patients with the expected cancer risk in the general population.

For the study, researchers in the Netherlands enrolled 3905 patients who had received treatment for Hodgkin's lymphoma between 1965 and 2000 and were 15 to 50 years of age at the time of treatment. Patients were included if they had survived for at least 5 years after the initiation of cancer therapy.

Results showed that at a median follow-up of 19.1 years, 908 patients were diagnosed with a total of 1055 second cancers, resulting in a standardized incidence ratio (SIR) of 4.6 (95% CI, 4.3 - 4.9) in the Hodgkin's lymphoma survivors compared with the general population. Researchers found that there was still an elevated risk of second malignant neoplasm 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 - 5.4).

The study demonstrated a cumulative incidence of a second cancer among Hodgkin's lymphoma survivors of 48.5% (95% CI, 45.4 - 51.5) at 40 years. There was no difference in the cumulative incidence of second solid cancers between 1965 to 1976, 1977 to 1988, or 1989 to 2000 (P = .71).

In regard to specific chemotherapy, researchers found that a cumulative procarbazine dose of 4.3 g/m2 or more was associated with a significantly lower risk for breast cancer (HR, 0.57; 95% CI, 0.39 - 0.84) but a higher risk for gastrointestinal cancer (HR, 2.70; 95% CI, 1.69 - 4.30).

The findings suggest that the risk of second solid cancers did not appear to be lower among patients treated between 1989 and 2000 than among survivors treated in earlier periods.

Reference

  1. Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015; 373(26):2499-2511.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters